Media coverage
3
Media coverage
Title RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis Media name/outlet PipelineReview Country/Territory Spain Date 17/03/22 URL https://pipelinereview.com/index.php/2022031780500/Small-Molecules/RINVOQ-upadacitinib-Receives-FDA-Approval-for-the-Treatment-of-Adults-with-Moderately-to-Severely-Active-Ulcerative-Colitis.html Persons Maria Abreu, Title AbbVie: RINVOQ (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis Media name/outlet India Pharma News Country/Territory India Date 16/03/22 Persons Maria Abreu, Title RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis Media name/outlet Wsiltv.com Country/Territory United States Date 16/03/22 URL https://www.wsiltv.com/news/illinois/rinvoq-upadacitinib-receives-fda-approval-for-the-treatment-of-adults-with-moderately-to-severely-active/article_227ea19b-1fc3-5292-b6c1-1c0fd0b7f793.html Persons Maria Abreu,